PDCD1 and neoplasm: Although the cytopathic activity of telomerase-specific replication-competent OBP-702 against Syrian hamster PDAC cells remains unclear, PDAC tumor models using Syrian hamster would be a more suitable model to evaluate the anti-tumor effect and safety of combination therapy with OBP-702 and PD-1 blockade.